FDA Expands Glaukos' iDose TR Implant Approval, Paving Way for Repeat Use in Glaucoma Management
Glaukos Corporation secures a significant FDA nod allowing repeated administration of its sustained-release iDose TR implant, broadening treatment options for patients with glaucoma and potentially reshaping long-term care paradigms.